Nick Tschernia, MD Profile Banner
Nick Tschernia, MD Profile
Nick Tschernia, MD

@NickTscherniaMD

Followers
215
Following
386
Media
30
Statuses
315

Doctor of Hematology/Oncology • Physician-Scientist • Immunotherapy fellow at NIH • Tweets are my own. He/him #Immunotherapy #Cancer

Washington, DC
Joined September 2020
Don't wanna be here? Send us removal request.
Explore trending content on Twitter
Nick Tschernia, MD Retweeted
@emilylmullin
Emily Mullin
3 days ago
Genomics company Illumina just unveiled its fastest, most cost-efficient DNA sequencer yet. The machine will deliver a $200 human genome and will be able to generate 20,000 of them a year.
24
347
1K
@NickTscherniaMD
Nick Tschernia, MD
3 days ago
71% ORR (35% CR/sCR), in 17 penta-exposed, largely high cytogenetic risk (n=13) pts w/ MM. G1/2 CRS in 15/17, except 1 G4 who had G4 ICANS/MAS. 11/17 w/ nail loss (10/11 resolved). 2/17 w/G3 Cerebellar tox. 1 w/delayed onset by ~6mo. Possibly🎯->Inf olivary nucleus w/⬆️GPRC5D exp
@ESmithMDPhD
Eric Smith
3 days ago
Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams. Happy to share our bench>bedside journey 1/10
Tweet media one
39
144
622
0
0
2
Nick Tschernia, MD Retweeted
@MaxMamonkin
Max Mamonkin
4 days ago
CAR T have many applications beyond direct tumor targeting. Here, we engineer T-cells to prevent acute GvHD after alloHSCT. We show targeted ablation of OX40+ T-cells reversed fatal xeno-GvHD and could be combined with a CAR to prevent leukemia relapse 1/
3
40
167
Nick Tschernia, MD Retweeted
@jitcancer
Journal for ImmunoTherapy of Cancer
5 days ago
New #JITC article: GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
Tweet media one
0
4
21
Nick Tschernia, MD Retweeted
@EricTopol
Eric Topol
8 days ago
Our metabolites indicate risk of more than 20 common diseases beyond traditional clinical risk factors New @NatureMedicine report from ~120,000 participants, >1.4 million person-years of follow-up @gogothorr @SteinfeldtJakob @berlinnovation @ChariteBerlin
Tweet media one
6
115
393
Nick Tschernia, MD Retweeted
@CapitiniMD
Christian Capitini
8 days ago
Superstar @OrentasR @seattlechildren is developing FGFR4 #CARTcells for #rhabdomyosarcoma A challenge for targeting solid tumor antigens is their low numbers on surface. Inhibiting myeloid cells helps CAR T efficacy @sitcancer @SidraMedicine #PMFG2022
Tweet media one
0
2
22
Nick Tschernia, MD Retweeted
@LabSchultze
Schultze Lab
9 days ago
Are you an immunologist & want to dive into the omics world? Then this might be a good start! Super excited to share our guide to systems-level immunomics, online now in @NatImmunol Congratulations to our very own @LorenzoBonaguro @jsschrepping @urealtomek
6
185
640
@NickTscherniaMD
Nick Tschernia, MD
9 days ago
In mouse models & human samples tumor cells evade immunotx by generating cell-in-cell structures resistant 2 killing by T cells & chemotx. Outer cells are killed by T cells, inner cells remain intact & disseminate once T cells are gone.🤯 We're going to need a bigger CAR.
Tweet media one
@SannaMadan
Sanna Madan
10 days ago
Biology is wild part 24853712: Cancer cells hide inside each other to stay safe from the immune system! 🕵️‍♀️ These transient "cell-in-cell structures" defy killing by T cells New important mechanism by which tumors are resistant to immunotherapy @eLife
2
38
179
0
0
0
Nick Tschernia, MD Retweeted
@BldCancerDoc
Navneet Majhail, MD, MS
10 days ago
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel #CARTcell in relapsed or refractory diffuse large B cell #lymphoma : higher efficacy and higher toxicity w/axi-cel vs. tisa-cel in 3rd+ line Rx for R/R DLBCL @NatureMedicine
2
11
44
Nick Tschernia, MD Retweeted
@MaxMamonkin
Max Mamonkin
11 days ago
Back in 2018, we were working to move our CD7 CARTs (CRISPR-edited for CD7 to avoid fratricide) to a Phase I but the regulatory hurdles for gene-edited CARTs were too high for a small academic group. That got us thinking, do we need gene editing at all? 1/
12
23
117
Nick Tschernia, MD Retweeted
@SannaMadan
Sanna Madan
15 days ago
How do immune cells stop themselves from aging & stay young? Turns out T cells can acquire telomerase from antigen-presenting cells and escape senescence! Fascinating new anti-aging mechanism used by the immune system for long-lasting protection
28
398
2K
Nick Tschernia, MD Retweeted
@GordanLauc
Gordan Lauc
17 days ago
Too many researchers are still ignoring glycans in their studies. To help them learn about the importance of glycosylation, all authors, and editors of the “Essential of Glycobiology” are donating their work to make this e-book free for everybody.
Tweet media one
38
504
2K
@NickTscherniaMD
Nick Tschernia, MD
17 days ago
Exciting implications for the expansion of CAR T cell tx into some autoimmune diseases, anti-CD19 CAR(4-1BB) tx w/ ongoing response off anti-SLE tx and 5-17mo of follow up. Safety profile as you might anticipate w/ comparatively low B cell burden: 3/5 (Grade 1 CRS), no ICANS.
@BLLPHD
Bruce Levine, Ph.D. 🇺🇦
17 days ago
👏CAR #TCell #immunotherapy applications are expanding, significant report @NatureMedicine Anti-CD19 CAR T cell therapy for refractory systemic #lupus erythematosus
Tweet media one
4
14
64
1
1
3
Nick Tschernia, MD Retweeted
@JoshuaHillMD
Joshua Hill, MD
19 days ago
In this paper, , we enrolled pre- and post-CAR-T cell therapy patients receiving SARS-CoV-2 vax. Humoral response poor pre-CAR-T, although T-cell responses were better and may recover after CAR-T infusion. Repeat vaccination post-CAR-T clearly important.
Tweet media one
4
17
65